0000950170-24-003632.txt : 20240110
0000950170-24-003632.hdr.sgml : 20240110
20240110161519
ACCESSION NUMBER: 0000950170-24-003632
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240108
FILED AS OF DATE: 20240110
DATE AS OF CHANGE: 20240110
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sepp-Lorenzino Laura
CENTRAL INDEX KEY: 0001777421
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37766
FILM NUMBER: 24526746
MAIL ADDRESS:
STREET 1: C/O INTELLIA THERAPEUTICS, INC.
STREET 2: 40 ERIE STREET, SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intellia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001652130
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 364785571
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-285-6200
MAIL ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
ownership.xml
4
X0508
4
2024-01-08
0001652130
Intellia Therapeutics, Inc.
NTLA
0001777421
Sepp-Lorenzino Laura
C/O INTELLIA THERAPEUTICS, INC.
40 ERIE STREET; SUITE 130
CAMBRIDGE
MA
02139
false
true
false
false
EVP, Chief Scientific Officer
true
Common Stock
2024-01-08
4
S
false
1608
28.66
D
44594
D
Common Stock
2024-01-08
4
S
false
667
29.38
D
43927
D
The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.16 to $29.06, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 8, 2024 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.19 to $29.63, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 8, 2024 at each separate price.
James Basta, attorney-in-fact
2024-01-10